cardiovascular disease

Thousand Oaks, Calif. – August 31, 2026 Amgen announced new Phase 3 findings showing that Repatha® (evolocumab) reduced the...

Tenax Therapeutics, Chapel Hill, North Carolina, August 29, 2026 Tenax Therapeutics announced the presentation of additional Phase 3 LEVEL...

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2026 Cytokinetics, Incorporated announced additional clinical data for aficamten from the ACACIA-HCM and...

PRINCETON, N.J., August 26, 2026 Bristol Myers Squibb presented new long-term data for Camzyos® (mavacamten) at the European Society...

Cambridge, Mass. – August 30, 2026 Alnylam Pharmaceuticals announced new clinical data at the European Society of Cardiology (ESC)...

Pasadena, Calif. – August 30, 2026 Arrowhead Pharmaceuticals presented detailed Phase 3 SHASTA-3 and SHASTA-4 data showing that plozasiran...

Zug, Switzerland & Boston, Mass. – August 28, 2026 CRISPR Therapeutics presented new Phase 1a durability data for CTX310,...

Dublin, Ireland & Bridgewater, N.J. – August 28, 2026 Amarin Corporation announced new post hoc findings from the landmark...

PALO ALTO, Calif., Aug. 26, 2026 BridgeBio Pharma, Inc. has announced that the first participant has been dosed in...

HEIDELBERG, Germany — August 25, 2026 Revier Therapeutics has officially launched operations following the closing of a €6 million...